

Publications by CR&T-Associated Researchers

Publications are continually being updated,
check back often for updates.



CR&T-Associated Researchers indicated in **bold**

2026

Silver RT, Hasselbalch HC. A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha. *Leukemia*. 2026 Apr 8. doi: 10.1038/s41375-026-02882-w. Epub ahead of print. PMID: 41951941

2025

Abu-Zeinah G, Hunter AM, Shatzel JJ, Yacoub A, Qin A, Chien HL, Mesa RA. Real-world analysis of polycythemia vera treatment reveals nonadherence to NCCN guidelines in a large proportion of patients. *Blood Neoplasia*. 2025 Sep 17;2(4):100167. doi: 10.1016/j.bneo.2025.100167. PMID: 41281612

Lee N Jr, **Erdos K**, Rahman AA, **Silver RT**, **Scandura JM**, **Abu-Zeinah G**. Low-dose ropeginterferon alfa-2b and peginterferon alfa-2a have comparable efficacy and tolerability in polycythemia vera. *Leuk Res*. 2025 Sep 19;158:108110. doi: 10.1016/j.leukres.2025.108110. Epub ahead of print. PMID: 41014693

Barbui T, Ghirardi A, Empson V, Fenili F, Loscocco GG, Condorelli A, Iurlo A, Cattaneo D, Rossi E, De Stefano V, Guglielmelli P, Klade C, Gisslinger H, Rambaldi A, **Scandura JM**, Vannucchi AM. Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera. *Blood Cancer J*. 2025 Aug 6;15(1):132. doi: 10.1038/s41408-025-01317-6. PMID: 40770048

Reeves BN, Masarova L, **Abu-Zeinah G**, Hunter AM, Shatzel JJ, Qin A, Yoon CH, Cai LY, Wei YF, Mesa RA. A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database. *Ann Hematol*. 2025 Jul 10. doi: 10.1007/s00277-025-06480-1. Epub ahead of print. PMID: 40637862.

Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, Lipton JH, Malhotra H, Niederwieser D, Radich J, Rousselot P, Saussele S, Schiffer CA, **Silver R**, Soverini S, Stenke L, Turkina A, Casado LF, Castagnetti F, Cervantes F, Clark RE, Cortes J, Deininger M,

Hughes TP, Janssen J, Jiang Q, Kim DW, Larson RA, Mahon FX, Mauro M, Mayer J, Nicolini FE, Pane F, Rea D, Richter J, Rosti G, Saglio G, Hehlmann R. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. *Leukemia*. 2025 Jul 11. doi: 10.1038/s41375-025-02664-w. Epub ahead of print. PMID: 40646132.

Karimi, A., Bogdani, C., O'Dwyer, E, **Siolas, D.** Emerging innovations in theranostics for pancreatic neuroendocrine tumors. *npj Precis. Onc.* 9, 146 (2025 May 19). doi.org/10.1038/s41698-025-00938-1

Krichevsky S, Sholle ET, Adekkanattu P, Abedian S, Ouseph M, Taylor E, **Abu-Zeinah G**, Jaber D, Sosner C, Cusick MM, Savage N, **Silver RT, Scandura JM**, Campion T. Automated Information Extraction from Unstructured Hematopathology Reports to Support Response Assessment in Myeloproliferative Neoplasms. *Methods Inf Med*. 2025 Apr 17. doi: 10.1055/a-2590-6456. Epub ahead of print. PMID: 40245940.

Abu-Zeinah G, Erdos K, Lee N, Ganom Y, Klade C, Krejcy K, Gisslinger H, **Silver RT, Scandura JM.** DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera. *Blood*. 2025 Apr 15: blood.2024027528. doi: 10.1182/blood.2024027528. Epub ahead of print. PMID: 40233320.

Erdos K, Alshareef A, **Silver RT, Scandura JM, Abu-Zeinah G**; Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis. *Blood Neoplasia* 2025; 100082. doi: <https://doi.org/10.1016/j.bneo.2025.100082>

Mascarenhas J, Bose P, Hillis C, Yacoub A, Chaer FEL, Maze D, **Abu-Zeinah G**, Qin A, Priego V, Tashi T, Cerquozzi S, Babu S, Foltz L, Goel S, Bhave RR, Lee S, Oh ST, Reeves B, Benton C, Fletcher L, Sirhan S, Safah H, Salib H, Villeneuve PJA, Zagrijtschuk O, Castro H, Masarova L. ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropoginterferon alfa-2b-njft in Polycythemia Vera. *Acta Haematol*. 2025 Mar 5:1-11. doi: 10.1159/000544818. Epub ahead of print. PMID: 40043697

Kucine N, Cario H, **Abu-Zeinah G**, Putti MC, Boissel N, Randi ML, Resar L, Griesshammer M, Kiladjian JJ. A Toolkit for Healthcare Transition for Adolescents With Classical Myeloproliferative Neoplasms. *Pediatr Blood Cancer*. 2025 Mar 4:e31633. doi: 10.1002/pbc.31633. Epub ahead of print. PMID: 40038897

Yacoub A, **Abu-Zeinah G**, Qin A, Tashi T, Da'na W, Shih WJ, Zagrijtschuk O, Tsai CY, Geller R, Komatsu N, Mesa R, Gill H. PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropoginterferon alfa-2b in patients with low- or high-risk polycythemia vera. *Ann Hematol*. 2025 Jan 13. doi: 10.1007/s00277-025-06185-5. Epub ahead of print. PMID: 39804351

2024

Abu-Zeinah G, Qin A, Gill H, Komatsu N, Mascarenhas J, Shih WJ, Zagrijtschuk O, Sato T, Shimoda K, **Silver RT**, Mesa R. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis. *Ann Hematol*. 2024 Sep;103(9):3573-3583. doi: 10.1007/s00277-024-05912-8. Epub 2024 Aug 15. PMID: 39145781; PMCID: PMC11358163.

Grunwald MR, **Ritchie EK**, Rumi E, Assad A, Hamer-Maansson JE, Yu J, Kalafut T, Braunstein E, Passamonti F. Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched-cohort analysis. *EJHaem*. 2024 Jul 19;5(4):778-783. doi: 10.1002/jha2.954. PMID: 39157625; PMCID: PMC11327719.

Abu-Zeinah G, **Erdos K**, **Lee N**, Lebbe A, Bouhali I, Khalid M, **Silver RT**, **Scandura JM**. Are thrombosis, progression, and survival in ET predictable? *Blood Cancer J*. 2024 Jun 25;14(1):103. doi: 10.1038/s41408-024-01079-7. PMID: 38918372; PMCID: PMC11199579.

Chamseddine RS, Savenkov O, Rana S, Khalid M, **Silver RT**, Kucine N, **Scandura JM**, **Abu-Zeinah G**. Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes. *Blood Adv*. 2024 May 28;8(10):2520-2526. doi: 10.1182/bloodadvances.2023012459. PMID: 38507746; PMCID: PMC11131058.

Izzo F, Myers RM, Ganesan S, Mekerishvili L, Kottapalli S, Prieto T, Eton EO, Botella T, Dunbar AJ, Bowman RL, Sotelo J, Potenski C, Mimitou EP, Stahl M, El Ghaity-Beckley S, Arandela J, Raviram R, Choi DC, Hoffman R, Chaligné R, Abdel-Wahab O, Smibert P, Ghobrial IM, **Scandura JM**, Marcellino B, Levine RL, Landau DA. Mapping genotypes to chromatin accessibility profiles in single cells. *Nature*. 2024 May;629(8014):1149-1157. doi: 10.1038/s41586-024-07388-y. Epub 2024 May 8. PMID: 38720070; PMCID: PMC11139586.

Kremyanskaya M, Kuykendall AT, Pemmaraju N, **Ritchie EK**, Gotlib J, Gerds A, Palmer J, Pettit K, Nath UK, Yacoub A, Molina A, Saks SR, Modi NB, Valone FH, Khanna S, Gupta S, Verstovsek S, Ginzburg YZ, Hoffman R; REVIVE Trial Investigators. Rusfertide, a Hcpidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. *N Engl J Med*. 2024 Feb 22;390(8):723-735. doi:10.1056/NEJMoa2308809. PMID: 38381675.

2023

Mascarenhas J, Kremyanskaya M, Patriarca A, Palandri F, Devos T, Passamonti F, Rampal RK, Mead AJ, Hobbs G, **Scandura JM**, Talpaz M, Granacher N, Somerville TCP, Hoffman R, Wondergem MJ, Salama ME, Colak G, Cui J, Kiladjian JJ, Vannucchi AM, Verstovsek S, Curto-García N, Harrison C, Gupta V. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. *J Clin Oncol*. 2023 Nov 10;41(32):4993-5004. doi:10.1200/JCO.22.01972. Epub 2023 Mar 7. PMID: 36881782; PMCID: PMC10642902.

Mora B, Maffioli M, Rumi E, Guglielmelli P, Caramella M, Kuykendall A, Palandri F, Iurlo A, De Stefano V, Kiladjian JJ, Elli EM, Polverelli N, Gotlib J, Albano F, **Silver RT**, Benevolo G, Ross DM, Devos T, Borsani O, Barbui T, Porta MGD, Bertù L, Komrokji R, Vannucchi AM, Passamonti F. Incidence of blast phase in

myelofibrosis according to anemia severity. *EJHaem*. 2023 Jul 17;4(3):679-689. doi: 10.1002/jha2.745. PMID: 37601878; PMCID: PMC10435699.

Silver RT, Abu-Zeinah G. Polycythemia vera: aspects of its current diagnosis and initial treatment. *Expert Rev Hematol*. 2023 Apr;16(4):253-266. doi: 10.1080/17474086.2023.2198698. PMID: 37013802.

Silver RT, Erdos K, Taylor E 3rd, Scandura JM, Abu-Zeinah G. Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival. *Leukemia*. 2023 Mar;37(3):691-694. doi: 10.1038/s41375-022-01793-w. Epub 2022 Dec 22. PMID: 36550213; PMCID: PMC10565714.

Abu-Zeinah K, Saadeh K, **Silver RT, Scandura JM, Abu-Zeinah G.** Excess mortality in younger patients with myeloproliferative neoplasms. *Leuk Lymphoma*. 2023 Mar;64(3):725-729. doi: 10.1080/10428194.2022.2070914. Epub 2022 May 9. PMID: 35532314.

2022

Flynn KE, Atallah E, Lin L, Shah NP, **Silver RT**, Larson RA, Panilla-Ibarz J, Thompson JE, Oehler VG, Radich JP, Kota V, Mauro MJ, Schiffer CA, Cortes J, Weinfurt KP. Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. *Haematologica*. 2022 Nov 1;107(11):2641-2649. doi: 10.3324/haematol.2021.280377. PMID: 35511672; PMCID: PMC9614525.

Mora B, Guglielmelli P, Kuykendall A, Rumi E, Maffioli M, Palandri F, De Stefano V, Caramella M, Salmoiraghi S, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Ruggeri M, **Silver RT**, Albano F, Benevolo G, Ross DM, Della Porta MG, Devos T, Rotunno G, Komrokji RS, Casetti IC, Merli M, Brociner M, Caramazza D, Auteri G, Barbui T, Cattaneo D, Bertù L, Arcaini L, Vannucchi AM, Passamonti F. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients. *Leukemia*. 2022 Oct;36(10):2453-2460. doi: 10.1038/s41375-022-01673-3. Epub 2022 Aug 30. PMID: 36042316.

Frindt G, Meyerson JR, Satty A, **Scandura JM**, Palmer LG. Expression of ENaC subunits in epithelia. *J Gen Physiol*. 2022 Oct 3;154(10):e202213124. doi: 10.1085/jgp.202213124. Epub 2022 Aug 8. PMID: 35939271; PMCID: PMC9387651.

Abu-Zeinah G, Di Giandomenico S, Choi D, Cruz T, **Erdos K, Taylor E, Ritchie EK, Silver RT, Scandura JM.** Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome. *Blood Adv*. 2022 Sep 27;6(18):5477-5481. doi: 10.1182/bloodadvances.2022007128. PMID: 35789232; PMCID: PMC9631704.

Patel AJ, Warda S, Maag JLV, Misra R, Miranda-Román MA, Pachai MR, Lee CJ, Li D, Wang N, Bayshtok G, Fishinevich E, Meng Y, Wong EWP, Yan J, Giff E, Pappalardi MB, McCabe MT, Fletcher JA, Rudin CM, Chandarlapaty S, **Scandura JM**, Koche RP, Glass JL, Antonescu CR, Zheng D, Chen Y, Chi P. PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. *Cancer Discov*. 2022 Sep 2;12(9):2120-2139. doi: 10.1158/2159-8290.CD-21-1671. PMID: 35789380; PMCID: PMC9437570.

Pemmaraju N, Verstovsek S, Mesa R, Gupta V, Garcia JS, **Scandura JM**, Oh ST, Passamonti F, Döhner K, Mead AJ. Defining disease modification in myelofibrosis in the era of targeted therapy. *Cancer*. 2022 Jul 1;128(13):2420-2432. doi: 10.1002/cncr.34205. Epub 2022 May 2. PMID: 35499819; PMCID: PMC9322520.

Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, Álvarez-Larrán A, De Stefano V, Guglielmelli P, Palandri F, Passamonti F, Barosi G, **Silver RT**, Hehlmann R, Kiladjian JJ, Barbui T. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. *Lancet Haematol*. 2022 Apr;9(4):e301-e311. doi: 10.1016/S2352-3026(22)00046-1. PMID: 35358444.

Harrison CN, Garcia JS, Somerville TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, **Ritchie EK**, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, Masud AA, Nuthalapati S, Potluri J, Pemmaraju N. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. *J Clin Oncol*. 2022 May 20;40(15):1671-1680. doi: 10.1200/JCO.21.02188. Epub 2022 Feb 18. PMID: 35180010; PMCID: PMC9113204.

Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, Harrison CN, McMullin MF, Vannucchi AM, Ewing J, O'Connell CL, Kiladjian JJ, Mead AJ, Winton EF, Leibowitz DS, De Stefano V, Arcasoy MO, Kessler CM, Catchatourian R, Rondelli D, **Silver RT**, Bacigalupo A, Nagler A, Kremyanskaya M, Levine MF, Arango Ossa JE, McGovern E, Sandy L, Salama ME, Najfeld V, Tripodi J, Farnoud N, Penson AV, Weinberg RS, Price L, Goldberg JD, Barbui T, Marchioli R, Tognoni G, Rampal RK, Mesa RA, Dueck AC, Hoffman R. A randomized phase 3 trial of interferon- α vs hydroxyurea in polycythemia vera and essential thrombocythemia. *Blood*. 2022 May 12;139(19):2931-2941. doi: 10.1182/blood.2021012743. PMID: 35007321; PMCID: PMC9101248.

Abu-Zeinah G, Silver RT, Abu-Zeinah K, Scandura JM. Normal life expectancy for polycythemia vera (PV) patients is possible. *Leukemia*. 2022 Feb;36(2):569-572. doi: 10.1038/s41375-021-01447-3. Epub 2021 Oct 8. PMID: 34625712.

Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, **Silver RT**, Thompson JE, Flynn KE. Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. *J Natl Cancer Inst*. 2022 Jan 11;114(1):160-164. doi: 10.1093/jnci/djab184. PMID: 34491344; PMCID: PMC8755495.

2021

Hasselbalch HC, **Silver RT.** New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms. *Hemasphere*. 2021 Nov 18;5(12):e645. doi: 10.1097/HS9.0000000000000645. PMID: 34805764; PMCID: PMC8601345.

***Abu-Zeinah G**, Krichevsky S, Cruz T, Hoberman G, Jaber D, Savage N, Sosner C, **Ritchie EK**, **Scandura JM**, **Silver RT**. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. *Leukemia*. 2021 Sep;35(9):2592-2601. doi: 10.1038/s41375-021-01183-8. Epub 2021 Mar 2. PMID: 33654206; PMCID: PMC8410882

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, **Silver RT**, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Tang D, Abraham P, Lord-Bessen J, Rose S, Guo S, Liao W, Mesa RA. Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. *Hemasphere*. 2021 Apr 29;5(5):e562. doi: 10.1097/HS9.0000000000000562. PMID: 33969275; PMCID: PMC8096470.

Hasselbalch HC, Elvers M, **Schafer AI**. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. *Blood*. 2021 Apr 22;137(16):2152-2160. doi: 10.1182/blood.2020008109. PMID: 33649757.

Schafer AI. Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms. *Hematol Oncol Clin North Am*. 2021 Apr;35(2):305-324. doi: 10.1016/j.hoc.2020.11.006. Epub 2021 Jan 5. PMID: 33641871.

Frankel AE, Reddy R, DeSuza KR, Deeb K, Carlin AF, Smith D, Xie Y, Naik E, **Silver RT**, Hasselbalch HC. Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib. *Clin Case Rep*. 2021 Mar 7;9(4):2228-2235. doi: 10.1002/ccr3.3997. PMID: 33936671; PMCID: PMC8077319.

Lee S, Desai P, Edirisinghe B, Pianello S, Curcio T, Samuel M, **Ritchie EK**, Roboz GJ. Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy. *Leuk Lymphoma*. 2021 Feb;62(2):498-500. doi: 10.1080/10428194.2020.1832674. Epub 2020 Oct 10. PMID: 33043735.

Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, **Ritchie EK**, **Silver RT**, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. *JAMA Oncol*. 2021 Jan 1;7(1):42-50. doi: 10.1001/jamaoncol.2020.5774. PMID: 33180106; PMCID: PMC7662490.

2020

Chaekal OK, Scaradavou A, Masson Frenet E, Albano MS, Cushing M, Desai P, Dobrila L, Gergis U, Guarneri D, Hsu JM, Lee S, Mayer SA, Phillips AA, Orfali N, **Ritchie EK**, Roboz GJ, Romeo C, Samuel MS, Shore T, van Besien K. Adoptive immunotherapy with CB following chemotherapy for patients with

refractory myeloid malignancy: chimerism and response. *Blood Adv.* 2020 Oct 27;4(20):5146-5156. doi: 10.1182/bloodadvances.2020002805. PMID: 33091124; PMCID: PMC7594383.

Abu-Zeinah G, DeSancho MT. Understanding Sideroblastic Anemia: An Overview of Genetics, Epidemiology, Pathophysiology and Current Therapeutic Options. *J Blood Med.* 2020 Sep 25;11:305-318. doi: 10.2147/JBM.S232644. PMID: 33061728; PMCID: PMC7524202.

Silver RT. Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one? *Haematologica.* 2020 Sep 1;105(9):2190-2191. doi: 10.3324/haematol.2020.256602. PMID: 33054041; PMCID: PMC7556626.

Di Giandomenico S, Kermani P, Mollé N, Yabut MM, **Abu-Zeinah G**, Stephens T, Messali N, Schreiner R, Brenet F, Rafii S, **Scandura JM**. Megakaryocyte TGF β 1 partitions erythropoiesis into immature progenitor/stem cells and maturing precursors. *Blood.* 2020 Aug 27;136(9):1044-1054. doi: 10.1182/blood.2019003276. PMID: 32548608; PMCID: PMC7453150.

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, **Silver RT**, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Shen J, Berry T, Brownstein C, Mesa RA. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. *Am J Hematol.* 2020 Jun;95(6):594-603. doi: 10.1002/ajh.25777. Epub 2020 Apr 17. PMID: 32129512; PMCID: PMC7317815.

Geyer JT, Margolskee E, Krichevsky SA, Cattaneo D, Boiocchi L, Ronchi P, Lunghi F, **Scandura JM**, Ponzoni M, Hasserjian RP, Gianelli U, Iurlo A, Orazi A. Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts ($\geq 10\%$) or with other types of disease progression. *Haematologica.* 2020 May;105(5):e221-e224. doi: 10.3324/haematol.2019.230193. Epub 2019 Sep 19. PMID: 31537690; PMCID: PMC7193506.

Hochhaus A, Baccarani M, **Silver RT**, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Sauße S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. *Leukemia.* 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3. PMID: 32127639; PMCID: PMC7214240.

Mollé N, Krichevsky S, Kermani P, **Silver RT**, **Ritchie E**, **Scandura JM**. Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. *Blood.* 2020 Mar 26;135(13):1062-1066. doi: 10.1182/blood.2019003050. PMID: 32047890.

Manur R, Sung PJ, Loren AW, **Ritchie EK**, Frank D, Bagg A, Geyer JT, Bogusz AM. Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation - diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib. *Leuk Lymphoma*. 2020 Feb;61(2):450-454. doi: 10.1080/10428194.2019.1660975. Epub 2019 Sep 16. PMID: 31524018.

Mora B, Guglielmelli P, Rumi E, Maffioli M, Barraco D, Rambaldi A, Caramella M, Komrokji RS, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, **Silver RT**, Albano F, Benevolo G, Cavalloni C, Uccella S, Accetta R, Siracusa C, Agnoli S, Merli M, Barbui T, Bertù L, Cazzola M, Vannucchi AM, Passamonti F. Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. *Am J Hematol*. 2020 Jan;95(1):E1-E3. doi: 10.1002/ajh.25644. Epub 2019 Nov 1. PMID: 31588594.

Cruz NM, Gergis U, **Silver RT**. Myelofibrosis: best practices, controversies and 2019 update. *Expert Rev Hematol*. 2020 Jan;13(1):71-84. doi: 10.1080/17474086.2020.1691519. Epub 2019 Nov 30. PMID: 31709843.

2019

Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, **Ritchie E**, **Silver RT**, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama ME, Weinberg RS, Rampal R, Goldberg JD, Mesa R, Dueck AC, Hoffman R. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. *Leukemia*. 2019 Dec;33(12):2974-2978. doi: 10.1038/s41375-019-0524-7. Epub 2019 Jul 30. PMID: 31363161; PMCID: PMC6884668.

Kim J, Krichevsky S, Xie L, Palumbo MC, Rodriguez-Diego S, Yum B, Brouwer L, **Silver RT**, **Schafer AI**, **Ritchie EK**, Yabut MM, Sosner C, Horn EM, Devereux RB, **Scandura JM**, Weinsaft JW. Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension. *J Am Soc Echocardiogr*. 2019 Dec;32(12):1574-1585. doi: 10.1016/j.echo.2019.07.010. Epub 2019 Oct 3. PMID: 31587969; PMCID: PMC6899198.

Silver RT, Krichevsky S. Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values. *Haematologica*. 2019 Nov;104(11):2200-2205. doi: 10.3324/haematol.2018.213108. Epub 2019 Apr 4. PMID: 30948488; PMCID: PMC6821600.

Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, **Ritchie E**, **Silver RT**, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. *Blood*. 2019 Oct 31;134(18):1498-1509. doi: 10.1182/blood.2019000428. PMID: 31515250; PMCID: PMC6839950.

Schafer AI, Mann DL. Current Education of Physicians: Lost in Translation? *JACC Basic Transl Sci.* 2019 Sep 23;4(5):655-657. doi: 10.1016/j.jacbts.2019.08.002. PMID: 31768480; PMCID: PMC6872778.

Publications only (abstracts not included)